



Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

06 May 2015

JANETTE LORETO- GARIN, MD, MBA-H

Secretary
Department of Health

Dear **Secretary Garin**:

After evaluating the documents submitted by the proponents pertinent to requests for reconsideration on the inclusion of the below listed medicines to the Philippine National Formulary (PNF), the Formulary Executive Council (FEC) respectfully recommends the **disapproval** of the said requests:

Drug	Dosage strength and formulation	FEC recommendation
1. Insulin glulisine	100 Units/mL solution for injection	Disapproval Insulin glulisine was found to be slightly better than regular insulin in terms of reduction in HbA1C and reaching target HbA1c. The advantage however is small and may not be clinically significant. It is also slightly better in terms of incidence of hypoglycemia. Similarly the advantage is small and may not be clinically significant. In terms of cost, insulin glulisine is more expensive by around 20% over regular insulin.
2. Insulin detemir	100 U/mL Solution for Injection (SC) 3mL penfill glass cartridge	Disapproval Insulin detemir was found to have no clinically significant advantage over NPH insulin and four times more expensive. Thus, there is not enough evidence to include insulin detemir in addition to NPH insulin in the formulary.
3. Biphasic insulin aspart 30	100U/mL suspension for injection 3mL prefilled pen	Disapproval The current evidence does not support including insulin aspart premix into the formulary. It has similar efficacy as biphasic human insulin and marginal advantage in preventing hypoglycemia. Likewise it is more expensive than the currently listed biphasic human insulin.

4. Insulin lispro (rDNA origin)	100 Units/mL solution for injection	Disapproval Insulin lispro has minimal advantage over regular insulin in terms efficacy and has a higher risk of side effects. Likewise, the cost is 20% more than regular insulin.
5. Insulin lispro mix (insulin lispro and insulin-lispro-protamine-sulfate)	100 Units/mL suspension for injection	Disapproval Insulin lispro mix has minimal advantage over regular insulin in terms of efficacy and safety. Likewise, the overall cost of treatment is 4 times with insulin lispro mix compared to biphasic human insulin.

We wish to inform you that all stakeholders were given 30 days to submit an application for reconsideration and the Council received appeals for insulin *aspart premix* and detemir, which were re-evaluated with the assistance from the Evidence Review Group. *Jan*

Attached herewith are the evidence summaries considered by the Council.

For your approval, Ma'am.

Very truly yours,

For the Formulary Executive Council

ISIDRO C. SIA
ISIDRO C. SIA
 Member

Approved / Disapproved:

JANETTE LORETO-GARIN
JANETTE LORETO- GARIN, MD, MBA-H
 Secretary of Health